Companies › Quoin Pharmaceuticals
1 active drug program in 6 registered trials: 6 Phase 2; Immunology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| QRX003 Lotion 2% Serine protease inhibitor | – | Phase 2 | Netherton Syndrome | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06953466 | QRX003 Lotion 2% | Phase 2 | Netherton Syndrome | Immunology | Dec 2026 |
| NCT05789056 | QRX003 Lotion 2% | Phase 2 | Netherton Syndrome | Immunology | Dec 2026 |
| NCT05521438 | QRX003 Lotion 2% | Phase 2 | Netherton Syndrome | Immunology | Dec 2026 |
| NCT05521438 | QRX003 Lotion 2% | Phase 2 | Netherton Syndrome | Immunology | Dec 2026 |
| NCT05521438 | QRX003 Lotion 2% | Phase 2 | Netherton Syndrome | Immunology | Dec 2026 |
| NCT07538583 | QRX003 Lotion 2% | Phase 2 | Netherton Syndrome | Immunology | Jan 2027 |
Cash and short-term investments of $33m on 2026-09-30; operating cash outflow about $18m a year; runway about 22 months at that burn, to Jul 2028; 4 of 4 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Aclaris Therapeutics Savara Alumis Toll Biotech Co. Ltd. (Beijing) Ventus Therapeutics U.S.
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.